Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Cardiol Therapeutics Inc’s stock clocked out at $1.06, down -4.50% from its previous closing price of $1.11. In other words, the price has decreased by -$4.50 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
To gain a deeper understanding of CRDL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.49. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on January 28, 2025, initiated with a Buy rating and assigned the stock a target price of $7.
On June 26, 2024, ROTH MKM started tracking the stock assigning a Buy rating and target price of $10.
On April 22, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $9.H.C. Wainwright initiated its Buy rating on April 22, 2024, with a $9 target price.
Stock Price History:
Over the past 52 weeks, CRDL has reached a high of $3.12, while it has fallen to a 52-week low of $1.02. The 50-Day Moving Average of the stock is -16.61%, while the 200-Day Moving Average is calculated to be -41.16%.
Shares Statistics:
A total of 81.60M shares are outstanding, with a floating share count of 77.72M. Insiders hold about 4.76% of the company’s shares, while institutions hold 9.73% stake in the company.
